Young Rock Chung

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/360240/publications.pdf

Version: 2024-02-01

32 papers	4,110 citations	430874 18 h-index	501196 28 g-index
32 all docs	32 docs citations	32 times ranked	8003 citing authors

#	Article	IF	Citations
1	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell, 2013, 23, 677-692.	16.8	706
2	ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression. Cancer Cell, 2012, 22, 180-193.	16.8	504
3	SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell, 2015, 27, 617-630.	16.8	449
4	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature Medicine, 2016, 22, 672-678.	30.7	301
5	Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine, 2015, 21, 1344-1349.	30.7	297
6	Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. Journal of Experimental Medicine, 2013, 210, 2641-2659.	8.5	278
7	Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5401-10.	7.1	238
8	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. New England Journal of Medicine, 2012, 367, 2316-2321.	27.0	222
9	Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell, 2018, 34, 225-241.e8.	16.8	162
10	Direct migration of follicular melanocyte stem cells to the epidermis after wounding or UVB irradiation is dependent on Mc1r signaling. Nature Medicine, 2013, 19, 924-929.	30.7	151
11	A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature, 2017, 549, 389-393.	27.8	144
12	Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery, 2015, 5, 64-71.	9.4	115
13	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood, 2017, 130, 397-407.	1.4	112
14	Hematopoietic Stem Cell Origin of BRAF V600E Mutations in Hairy Cell Leukemia. Science Translational Medicine, 2014, 6, 238ra71.	12.4	102
15	KMT2C mediates the estrogen dependence of breast cancer through regulation of ERÎ± enhancer function. Oncogene, 2018, 37, 4692-4710.	5.9	102
16	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature Communications, 2017, 8, 15429.	12.8	55
17	Epigenetic alterations in hematopoietic malignancies. International Journal of Hematology, 2012, 96, 413-427.	1.6	48
18	Early type I IFN blockade improves the efficacy of viral vaccines. Journal of Experimental Medicine, 2020, 217, .	8.5	38

#	Article	IF	Citations
19	Interrogating Adaptive Immunity Using LCMV. Current Protocols in Immunology, 2020, 130, e99.	3.6	19
20	TLR4 signaling improves PD-1 blockade therapy during chronic viral infection. PLoS Pathogens, 2019, 15, e1007583.	4.7	17
21	Femoral Bone Marrow Aspiration in Live Mice. Journal of Visualized Experiments, 2014, , .	0.3	12
22	Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors. Science Translational Medicine, 2019, 11, .	12.4	12
23	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine, 2016, 22, 578-579.	30.7	7
24	Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity. Blood, 2016, 128, 961-961.	1.4	6
25	Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis. Blood, 2015, 126, 4-4.	1.4	4
26	Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia. Blood, 2015, 126, 449-449.	1.4	3
27	Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses. Blood, 2016, 128, 951-951.	1.4	3
28	ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis. Blood, 2015, 126, 302-302.	1.4	2
29	Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is Required for Adult and Embryonic Hematopoiesis and Has Non-Overlapping Roles with SRSF2 in Hematopoiesis. Blood, 2016, 128, 1478-1478.	1.4	1
30	Conditional Deletion of Asxl1 Results in Myelodysplasia. Blood, 2012, 120, 308-308.	1.4	0
31	Oncogenic Mutations in XPO1 Promote Lymphoid Transformation By Altering Nuclear/Cytoplasmic Localization of NFÎºB Signaling Intermediates. Blood, 2017, 130, 879-879.	1.4	0
32	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. Blood, 2017, 130, 794-794.	1.4	0